comparemela.com

Latest Breaking News On - Harrow health - Page 3 : comparemela.com

Melt Pharmaceuticals raises $24M in Series B

Company to begin human trials on opioid- and needle-free sedation drug

United statesLarry dillahaNewbridge securities corpMelt pharmaceuticalsSecurities corpHarrow healthMelt pharmaceuticalsHarrow health

Harrow Health, Inc (NASDAQ:HROW) CEO Buys $104,310 00 in Stock

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) CEO Mark L. Baum acquired 9,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now […]

Markl baumSurface ophthalmics incRice hall james associatesHarrow health company profileJump financialStifel financial corpHarrow healthKennedy capital managementPharmaceuticals incNews ratings for harrow health dailyHarrow health stockHarrow health incInstitutional investors weigh in on harrow healthEton pharmaceuticals incGet free reportCapital management

Harrow Health, Inc 11 875% Senior Notes due 2027 (NASDAQ:HROWM) Short Interest Update

Harrow Health, Inc 11 875% Senior Notes due 2027 (NASDAQ:HROWM) Short Interest Update
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Harrow health incNews ratings for harrow health incHarrow healthSenior notesGet free report

Harrow Health, Inc Expected to Post Q1 2024 Earnings of ($0 25) Per Share (NASDAQ:HROW)

Harrow Health, Inc Expected to Post Q1 2024 Earnings of ($0 25) Per Share (NASDAQ:HROW)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Markl baumHarrow health tradingInstitutional trading of harrow healthBlackrock incVanguard group incPharmaceuticals incHarrow healthOpaleye management incMorgan stanleyInsider activity at harrow healthSecurities exchange commissionEton pharmaceuticals incSurface ophthalmics incNews ratings for harrow health dailyHarrow health incFree report

Harrow Health, Inc (NASDAQ:HROW) Expected to Earn Q1 2024 Earnings of ($0 25) Per Share

Harrow Health, Inc. (NASDAQ:HROW – Free Report) – Investment analysts at B. Riley issued their Q1 2024 earnings per share estimates for shares of Harrow Health in a research note issued to investors on Thursday, March 21st. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.25) per share for the […]

Eton pharmaceuticals incGoldman sachs group incHarrow healthNuveen asset managementHarrow health stockBarclays plcSurface ophthalmics incPricet rowe associates incNews ratings for harrow health dailyVanguard group incHedge funds weigh in on harrow healthOpaleye management incHarrow health incPharmaceuticals incFree reportSachs group

vimarsana © 2020. All Rights Reserved.